ArticleThe Journal of nutrition2013
Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.
Article in The Journal of nutrition, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- Dietary Patterns and Age-Related Macular Degeneration: A Matched Case-Control Study.Nutrients · 2026Article
- Clinical management of eye diseases: carotenoids and their nanoformulations as choice of therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA): A Targeted Antioxidant Strategy to Counter Oxidative Stress in Retinopathy.Antioxidants (Basel, Switzerland) · 2024Review
- Retinal Docosahexaenoic Acid Is Significantly Reduced in Diabetic Humans and Mice: Possible Relationship to Diabetic Retinopathy.Investigative ophthalmology & visual science · 2024Article
- Novel Therapeutic Effects ofPharmaceuticals (Basel, Switzerland) · 2024Article
- In Vivo Correlation Between Macular Pigment Optical Volume and Retinal Layers Thickness.Investigative ophthalmology & visual science · 2024Observational
- The Role of Oral Supplementation for the Management of Age-Related Macular Degeneration: A Narrative Review.Journal of personalized medicine · 2024Review
- Protective Effects ofAntioxidants (Basel, Switzerland) · 2023Article
- Protective Effect ofAntioxidants (Basel, Switzerland) · 2022Article
- The level and efficacy of lutein in patients with age-related macular degeneration: a comprehensive systematic review and meta-analysis.Annals of translational medicine · 2022Article
- Advanced glycation end products in diabetic retinopathy and phytochemical therapy.Frontiers in nutrition · 2022Review
- Review of Evidence for the Usage of Antioxidants for Eye Aging.BioMed research international · 2022Review
- Article
- Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications.Redox biology · 2020Review
- Lutein Supplementation for Eye Diseases.Nutrients · 2020Review
- Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors.Oxidative medicine and cellular longevity · 2020Review
- Standardizing the Assessment of Macular Pigment Using a Dual-Wavelength Autofluorescence Technique.Translational vision science & technology · 2019Article
- Effects of Fish n-3 PUFAs on Intestinal Microbiota and Immune System.Marine drugs · 2019Review
- Omega-3 fatty acids supplementation protects the retina from age-associated degeneration in aged C57BL/6J mice.BMJ open ophthalmology · 2019Article
- Models of retinal diseases and their applicability in drug discovery.Expert opinion on drug discovery · 2018Review
Corrections and comments
- Erratum issuedERRATUM.2013
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
The Age-Related Eye Diseases Study 2 (AREDS2) clinical trial is assessing the effects of higher dietary xanthophyll (lutein and zeaxanthin) and long-chain n3 polyunsaturated fatty acid (LCPUFA) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) intake on progression to advanced age-related macular degeneration (AMD). This study's purpose was to examine the retinal effects of the AREDS2 formulation on Chemokine (C-C motif) ligand 2 (Ccl2(-/-))/CX3C chemokine receptor 1 (Cx3cr1(-/-)) mice on Crumbs homolog 1 retinal degeneration phenotype 8 (Crb1(rd8)) background (DKO), which develop focal retinal lesions with certain features similar to AMD. DKO and C57BL/6N rd8 background mice (WT) were bred and randomized into 4 groups. Two groups, WT mice on AREDS2 diet (A-WT) and DKO mice on AREDS2 diet (A-DKO), were supplemented daily with 1.76 μmol of lutein, 35.1 μmol of zeaxanthin, 215 μmol EPA, and 107 μmol of DHA, and 2 control groups, WT mice on control diet (C-WT) and DKO mice on control diet (C-DKO), were fed an isocaloric diet. All mice had monthly fundus photos and were killed after 3 mo for biochemical and histologic analyses. After 3 mo, 81% of A-DKO mice had lesion regression compared with 25% of C-DKO mice (P < 0.05). Toxic retinal 2-[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetra-enyl]-1-(2-hydroxyethyl)-4-[4-methyl-6(2,6,6-trimethyl-1-cyclohexen-1-yl) 1E,3E,5E,7E-hexatrienyl]-pyridinium (A2E) concentrations were significantly lower in A-DKO compared with C-DKO mice. The outer nuclear layer thickness in A-DKO mice was significantly greater than that in C-DKO mice. Retinal expression of inducible nitric oxide synthase (iNos) tumor necrosis factor-α (Tnf-α), Cyclooxygenase-2 (Cox-2), interleukin1beta (IL-1β), and vascular endothelial growth factor (Vegf) was significantly lower in A-DKO compared with C-DKO mice. Xanthophylls and LCPUFAs have antiinflammatory, neuroprotective, and antiangiogenic properties. Our data provide potential mechanisms by which the AREDS2 formula has a protective effect on retinal lesions in DKO mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.